Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors in Type 2 Diabetes: A Literature Review of Approved Products

Lucio R. Volino^1,2, Eva Y. Pan¹, Rupal Patel Mansukhani^1,3

¹Department of Pharmacy Practice and Administration, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, USA.
²The Great Atlantic and Pacific Tea Company, Kenilworth, USA.
³Morristown Medical Center, Morristown, USA.

DOI: 10.4236/pp.2014.511114                

Abstract

Diabetes mellitus continues to be a major health issue worldwide. Despite all of the treatment options available on the market, many patients with diabetes fail to reach their treatment goals. Novel agents such as the Sodium-Glucose Cotransporter 2 (SGLT2) inhibitors show promise in effectively lowering blood glucose. Objective: To review the scientific literature for efficacy information regarding the use of approved SGLT2 inhibitors (canagliflozin, dapagliflozin and empagliflozin) in the treatment of Type 2 Diabetes Mellitus (T2DM). Methods: A MEDLINE (1950-August 2014) literature review was performed. All of the literature published as an original clinical trial was included in this review. Other pertinent articles published related to the original clinical trial were also included. Meta-analysis type studies were not selected for this review. Conclusions: With an increasing prevalence and incidence of type 2 diabetes mellitus worldwide, there is an apparent need for effective therapeutic strategies to combat this chronic and progressive disease. SGLT2 inhibitors offer this potential. Recently approved agents (canagliflozin, dapagliflozin and empagliflozin) have shown significant promise as mono- and add-on therapy to current glucose-lowering regimens that may not otherwise be providing sufficient glycemic control in T2DM patients.

Keywords

Canagliflozin, Dapagliflozin, SGLT2 Inhibitors, Type 2 Diabetes Mellitus, Empagliflozin

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Centers for Disease Control and Prevention (2012) Diabetes Data & Trends. Department of Health and Human Services, Atlanta. http://apps.nccd.cdc.gov/DDTSTRS/default.aspx
[2]	(2014) Farxiga (Dapagliflozin) (Prescribing Information). Bristol-Myers Squibb Company, Princeton.
[3]	(2014) Jardiance (Empagliflozin) (Prescribing Information). Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield.
[4]	(2013) Invokana (Canagliflozin) (Prescribing Information). Janssen Pharmaceuticals, Titusville.
[5]	Hardman, T.C. and Dubrey, S.W. (2011) Development and Potential Role of Type-2 Sodium-Glucose Transporter Inhibitors for Management of Type 2 Diabetes. Diabetes Therapy, 2, 133-145. http://dx.doi.org/10.1007/s13300-011-0004-1
[6]	Freeman, J.S. (2013) Review of Insulin-Dependent and Insulin-Independent Agents for Treating Patients with Type 2 Diabetes Mellitus and Potential Role for Sodium-Glucose Co-Transporter 2 Inhibitors. Postgraduate Medicine, 125, 214-226. http://dx.doi.org/10.3810/pgm.2013.05.2672
[7]	Rosenstock, J., Aggarwal, N., Polidori, D., Zhao, Y., Arbit, D., Usiskin, K., et al. (2012) Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-On to Metformin in Subjects with Type 2 Diabetes. Diabetes Care, 35, 1232-1238. http://dx.doi.org/10.2337/dc11-1926
[8]	Bode, B., Stenlöf, K., Sullivan, D., Fung, A. and Usiskin, K. (2013) Efficacy and Safety of Canagliflozin Treatment in Older Subjects with Type 2 Diabetes Mellitus: A Randomized Trial. Hospital Practice, 41, 72-84. http://dx.doi.org/10.3810/hp.2013.04.1020
[9]	Cefalu, W.T., Leiter, L.A., Yoon, K.H., Arias, P., Niskanen, L., Xie, J., et al. (2013) Efficacy and Safety of Canagliflozin versus Glimepiride in Patients with Type 2 Diabetes Inadequately Controlled with Metformin (CANTATA-SU): 52 Week Results from a Randomised, Double-Blind, Phase 3 Non-Inferiority Trial. The Lancet, 382, 941-950. http://dx.doi.org/10.1016/S0140-6736(13)60683-2
[10]	Inagaki, N., Kondo, K., Yoshinari, T., Maruyama, N., Susuta, Y. and Kuki, H. (2013) Efficacy and Safety of Canagliflozin in Japanese Patients with Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, 12-Week Study. Diabetes, Obesityand Metabolism, 15, 1136-1145. http://dx.doi.org/10.1111/dom.12149
[11]	Lavalle-González, F.J., Januszewicz, A., Davidson, J., Tong, C., Qiu, R., Canovatchel, W., et al. (2013) Efficacy and Safety of Canagliflozin Compared with Placebo and Sitagliptin in Patients with Type 2 Diabetes on Background Metformin Monotherapy: A Randomised trial. Diabetologia, 56, 2582-2592. http://dx.doi.org/10.1007/s00125-013-3039-1
[12]	Schernthaner, G., Gross, J.L., Rosenstock, J., Guarisco, M., Fu, M., Yee, J., et al. (2013) Canagliflozin Compared with Sitagliptin for Patients with Type 2 Diabetes Who Do Not Have Adequate Glycemic Control with Metformin Plus Sulfonylurea: A 52-Week Randomized Trial. Diabetes Care, 36, 2508-2515. http://dx.doi.org/10.2337/dc12-2491
[13]	Stenlöf, K., Cefalu, W.T., Kim, K.A., Alba, M., Usiskin, K., Tong, C., et al. (2013) Efficacy and Safety of Canagliflozin Monotherapy in Subjects with Type 2 Diabetes Mellitus Inadequately Controlled with Diet and Exercise. Diabetes, Obesity and Metabolism, 15, 372-382. http://dx.doi.org/10.1111/dom.12054
[14]	Wilding, J.P., Charpentier, G., Hollander, P., González-Gálvez, G., Mathieu, C., Vercruysse, F., et al. (2013) Efficacy and Safety of Canagliflozin in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Metformin and Sulphonylurea: A Randomised Trial. International Journal of Clinical Practice, 67, 1267-1282. http://dx.doi.org/10.1111/ijcp.12322
[15]	Yale, J.F., Bakris, G., Cariou, B., Yue, D., David-Neto, E., Xi, L., et al. (2013) Efficacy and Safety of Canagliflozin in Subjects with Type 2 Diabetes and Chronic Kidney Disease. Diabetes, Obesity and Metabolism, 15, 463-473. http://dx.doi.org/10.1111/dom.12090
[16]	Forst, T., Guthrie, R., Goldenberg, R., Yee, J., Vijapurkar, U., Meininger, G., et al. (2014) Efficacy and Safety of Canagliflozin over 52 Weeks in Patients with Type 2 Diabetes on Background Metformin and Pioglitazone. Diabetes, Obesity Metabolism, 16, 467-477. http://dx.doi.org/10.1111/dom.12273
[17]	Burki, T.K. (2012) FDA Rejects Novel Diabetes Drug over Safety Fears. The Lancet, 379, 507. http://dx.doi.org/10.1016/S0140-6736(12)60216-5
[18]	Bailey, C.J., Gross, J.L., Pieters, A., Bastien, A. and List, J.F. (2010) Effect of Dapagliflozin in Patients with Type 2 Diabetes Who Have Inadequate Glycaemic Control with Metformin: A Randomised, Double-Blind, Placebo-Controlled Trial. The Lancet, 375, 2223-2233. http://dx.doi.org/10.1016/S0140-6736(10)60407-2
[19]	Bailey, C.J., Iqbal, N., T’joen, C. and List, J.F. (2012) Dapagliflozin Monotherapy in Drug-Naïve Patients with Diabetes: A Randomized-Controlled Trial of Low-Dose Range. Diabetes, Obesity and Metabolism, 14, 951-959. http://dx.doi.org/10.1111/j.1463-1326.2012.01659.x
[20]	Bailey, C.J., Gross, J.L., Hennicken, D., Iqbal, N., Mansfield, T.A. and List, J.F. (2013) Dapagliflozin Add-On to Metformin in Type 2 Diabetes Inadequately Controlled with Metformin: A Randomized, Double-Blind, Placebo-Controlled 102-Week Trial. BMC Medicine, 11, 43. http://dx.doi.org/10.1186/1741-7015-11-43
[21]	Ferrannini, E., Ramos, S.J., Salsali, A., Tang, W. and List, J.F. (2010) Dapagliflozin Monotherapy in Type 2 Diabetic Patients with Inadequate Glycemic Control by Diet and Exercise: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial. Diabetes Care, 33, 2217-2224. http://dx.doi.org/10.2337/dc10-0612
[22]	Henry, R.R., Murray, A.V., Marmolejo, M.H., Hennicken, D., Ptaszynska, A. and List, J.F. (2012) Dapagliflozin, Metformin XR, or Both: Initial Pharmacotherapy for Type 2 Diabetes, a Randomised Controlled Trial. International Journal of Clinical Practice, 66, 446-456. http://dx.doi.org/10.1111/j.1742-1241.2012.02911.x
[23]	Kaku, K., Inoue, S., Matsuoka, O., Kiyosue, A., Azuma, H., Hayashi, N., et al. (2013) Efficacy and Safety of Dapagliflozin as a Monotherapy for Type 2 Diabetes Mellitus in Japanese Patients with Inadequate Glycaemic Control: A Phase II Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial. Diabetes, Obesity and Metabolism, 15, 432-440. http://dx.doi.org/10.1111/dom.12047
[24]	Nauck, M.A., Del Prato, S., Meier, J.J., Durán-García, S., Rohwedder, K., Elze, M., et al. (2011) Dapagliflozin versus Glipizide as Add-On Therapy in Patients with Type 2 Diabetes Who Have Inadequate Glycemic Control with Metformin: A Randomized, 52-Week, Double-Blind, Active-Controlled Noninferiority Trial. Diabetes Care, 34, 2015-2022. http://dx.doi.org/10.2337/dc11-0606
[25]	Rosenstock, J., Vico, M., Wei, L., Salsali, A. and List, J.F. (2012) Effects of Dapagliflozin, an SGLT2 Inhibitor, on HbA1c, Body Weight, and Hypoglycemia Risk in Patients with Type 2 Diabetes Inadequately Controlled on Pioglitazone Monotherapy. Diabetes Care, 35, 1473-1478. http://dx.doi.org/10.2337/dc11-1693
[26]	Strojek, K., Yoon, K.H., Hruba, V., Elze, M., Langkilde, A.M. and Parikh, S. (2011) Effect of Dapagliflozin in Patients with Type 2 Diabetes Who Have Inadequate Glycaemic Control with Glimepiride: A Randomized, 24-Week, Double-Blind, Placebo-Controlled Trial. Diabetes, Obesity and Metabolism, 13, 928-938. http://dx.doi.org/10.1111/j.1463-1326.2011.01434.x
[27]	Wilding, J.P., Norwood, P., Tjoen, C., Bastien, A., List, J.F. and Fiedorek, F.T. (2009) A Study of Dapagliflozin in Patients with Type 2 Diabetes Receiving High Doses of Insulin Plus Insulin Sensitizers: Applicability of a Novel Insulin-Independent Treatment. Diabetes Care, 32, 1656-1662. http://dx.doi.org/10.2337/dc09-0517
[28]	Wilding, J.P., Woo, V., Soler, N.G., Pahor, A., Sugg, J., Rohwedder, K., et al. (2012) Long-Term Efficacy of Dapagliflozin in Patients with Type 2 Diabetes Mellitus Receiving High Doses of Insulin: A Randomized Trial. Annals of Internal Medicine, 156, 405-415. http://dx.doi.org/10.7326/0003-4819-156-6-201203200-00003
[29]	Heise, T., Seewaldt-Becker, E., Macha, S., Hantel, S., Pinnetti, S., Seman, L., et al. (2013) Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Following 4 Weeks’ Treatment with Empagliflozin Once Daily in Patients with Type 2 Diabetes. Diabetes, Obesity and Metabolism, 15, 613-621. http://dx.doi.org/10.1111/dom.12073
[30]	Ferrannini, E., Seman, L., Seewaldt-Becker, E., Hantel, S., Pinnetti, S. and Woerle, H.J. (2013) A Phase IIb, Randomized, Placebo-Controlled Study of the SGLT2 Inhibitor Empagliflozin in Patients with Type 2 Diabetes. Diabetes, Obesity and Metabolism, 15, 721-728. http://dx.doi.org/10.1111/dom.12081
[31]	Rosenstock, J., Seman, L.J., Jelaska, A., Hantel, S., Pinnetti, S., Hach, T., et al. (2013) Efficacy and Safety of Empagliflozin, a Sodium Glucose Cotransporter 2 (SGLT2) Inhibitor, as Add-On to Metformin in Type 2 Diabetes with Mild Hyperglycaemia. Diabetes, Obesity and Metabolism, 15, 1154-1160. http://dx.doi.org/10.1111/dom.12185